Caprock Group’s BioNTech BNTX Stock Holding History

Caprock Group’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,558	Closed	-$206K	–	912
2024 Q2	$206K	Buy	+2,558	New	+$234K	0.01%	800

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

CII

Capital International Inc Los Angeles, California $13B AUM 31.88% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caprock Group's BNTX Position: Q3 2024 in Review

Caprock Group sold out of BioNTech (BNTX) in Q3 2024, closing a stake of 2,558 shares — an estimated $206K sold.

Caprock Group first reported a position in BNTX in Q2 2024 and held it in 1 quarter. The position peaked at $206K in Q2 2024. 296 funds tracked by Wall St. Rank hold BNTX as of Q3 2024.

Caprock Group reported no remaining BioNTech position as of Q3 2024 after selling out during the quarter.
Caprock Group sold 2,558 BioNTech shares in Q3 2024, an estimated $206K.
Caprock Group first reported a position in BioNTech in Q2 2024 and held it in 1 quarter.
Caprock Group's BioNTech position peaked at $206K in Q2 2024.
296 funds tracked by Wall St. Rank held BioNTech as of Q3 2024.

Based on Caprock Group's 13F filing for Q3 2024, filed 7 Nov 2024.